EconStor >
Stockholm School of Economics >
EFI - The Economic Research Institute, Stockholm School of Economics >
SSE/EFI Working Paper Series in Economics and Finance, EFI - The Economic Research Institute, Stockholm School of Economics >

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10419/56153
  

Full metadata record

DC FieldValueLanguage
dc.contributor.authorKobelt, Giselaen_US
dc.contributor.authorLindgren, Peteren_US
dc.contributor.authorSmala, Antjeen_US
dc.contributor.authorJönsson, Bengten_US
dc.date.accessioned2012-03-28T13:04:47Z-
dc.date.available2012-03-28T13:04:47Z-
dc.date.issued2000en_US
dc.identifier.urihttp://hdl.handle.net/10419/56153-
dc.description.abstractWe performed a cross-sectional, bottom-up observational study of resource consumption and quality of life of patients with multiple sclerosis (MS) in Germany. Six centers participated in the study. Patients were asked to complete a questionnaire, and a total of 737 patients returned the questionnaire (the answer rate being 66%). The questionnaire provided information on all resource consumption, medical and non-medical, work absence and informal care related to their MS. Simultaneously, medical charts were also abstracted for a sub sample of 202 patients. For this sub sample, disease scores (Expanded Disability Status Scale, EDSS) were available from the study centers. For the remainder, disease scores were assigned using a matrix of disease (mobility) descriptions and EDSS scores. Mean total cost per patient and year was 65,400 DM, adjusted for usage of interferons, which was higher in this sample than the current average usage in Germany. When this cost is extrapolated to an estimated patient population of 120,000, total costs to society are estimated at 7.85 billion DM. Direct costs represented 57.5%, informal care accounted for 12.1% and indirect costs amounted to 42.5%. An estimated 24,800 DM per patient or 38% of total costs are paid for by public payers. Intangible costs were estimated 16,650 DM per patient and year. The mean age of the cohort was 42 years (disease onset 33), the mean utility measured with EQ-5D was 0.552 (0.919 to -0.429), and the mean EDSS score 4.4 (1.0 to 9.5). All costs (direct, informal care, indirect) increased with increasing EDSS scores, while utilities decreased.en_US
dc.language.isoengen_US
dc.publisherEkonomiska Forskningsinst. Stockholmen_US
dc.relation.ispartofseriesSSE/EFI Working Paper Series in Economics and Finance 399en_US
dc.subject.jelD61en_US
dc.subject.jelH42en_US
dc.subject.jelH51en_US
dc.subject.jelH55en_US
dc.subject.jelI18en_US
dc.subject.ddc330en_US
dc.subject.keywordmultiple sclerosisen_US
dc.subject.keywordcost-of-illnessen_US
dc.subject.keywordquality of lifeen_US
dc.subject.keywordEDSSen_US
dc.subject.keywordutilityen_US
dc.subject.stwKrankheiten_US
dc.subject.stwKostenen_US
dc.subject.stwLebensqualitäten_US
dc.subject.stwStatistischer Testen_US
dc.subject.stwDeutschlanden_US
dc.titleCosts and quality of life in multiple sclerosis: A cross-sectional observational study in Germanyen_US
dc.typeWorking Paperen_US
dc.identifier.ppn333187628en_US
dc.rightshttp://www.econstor.eu/dspace/Nutzungsbedingungenen_US
Appears in Collections:SSE/EFI Working Paper Series in Economics and Finance, EFI - The Economic Research Institute, Stockholm School of Economics

Files in This Item:
File Description SizeFormat
333187628.pdf333.38 kBAdobe PDF
No. of Downloads: Counter Stats
Show simple item record
Download bibliographical data as: BibTeX

Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.